Psilocybin therapy for depression in Parkinson's disease
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests whether psilocybin, a substance found in certain mushrooms, can help improve depression in people with Parkinson's disease. If you have Parkinson's and are feeling depressed, this treatment may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old
- You have been diagnosed with Parkinson's disease by a neurologist
- You are currently experiencing symptoms of depression
- You can travel to UCSF for in-person visits and join virtual visits
- You have a doctor who is managing your care and can be contacted
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether psilocybin (a psychedelic compound) combined with therapy can reduce depression in people with Parkinson's disease. If you have moderate-to-severe depression and Parkinson's, this trial may offer a new treatment option.
This trial tests whether a medicine called psilocybin (the active ingredient in 'magic mushrooms') combined with therapy can help treat depression. You would have a few sessions with a therapist and receive the medicine in a safe setting, which might improve your mood.
This trial tests whether psilocybin can help people with major depression who are currently having a depressive episode. It aims to understand how the treatment works and if it is safe and effective.
This early-phase study tests whether psilocybin (a psychedelic substance) can help with depression in people who have mild memory problems or early Alzheimer’s. The trial also closely monitors safety, thinking changes, mood, and blood pressure before and after dosing.
This study tests if psilocybin (a psychedelic) combined with cognitive behavioral therapy (CBT) can help people with major depression. You would receive the psilocybin in a supervised setting and have talk therapy before and after.
This trial tests whether a single dose of psilocybin (a psychedelic medicine) can help reduce depression and distress in people with advanced lung disease, ALS, multiple sclerosis, or Parkinson's. You would receive preparation, the drug, and follow-up support in a safe, supervised setting.
Hear when a new Depression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.